Table 2.

Characteristics of patient cohort

Patients		116
Age (years)		62.5 (range 26–93)
Gender		Female: n = 56 (48.3%); male: n = 60 (51.7%)
Median BMI (kg/m2)		24.89 (range 15.57–46.87)
At least one cardiovascular risk factor		n = 55 (47%)
Treatment
Ipilimumab before	Total: n = 44
	Nivolumab: n = 24
	Pembrolizumab: n = 19
	Both: n = 1
Ipilimumab concomitantly	n = 8
Ipilimumab after anti PD-1	n = 4
Nivolumab/pembrolizumab	n = 55/n = 61
Median anti PD-1 therapy duration	5 months (0.5;39)
Median line number	2 with 4 re-challenges
Concomitant corticosteroid treatment	n = 32 (28%)
Immunotherapy-related adverse events
Side effects	Ipilimumab: n = 16
	Anti PD-1: n = 25
	Concomitant treatment n = 3
Ipilimumab	Hypophysitis n = 10
	Colitis n = 4
	Hepatitis n = 2
Nivolumab/pembrolizumab	Meningitis n = 1
	Hepatitis n = 4
	Thyroiditis n = 9
	Pneumonitis n = 5
	Hypophysitis n = 3
	Vitiligo n = 2
	Surrenal insufficiency n = 1
Ipilimumab + nivolumab	Colitis n = 1
	Hypophysitis n = 1
	Hepatitis n = 1